ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.

85,013 comparisons

Most participants first33,758 with no events in either group come last521 to 540 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Use for Children With Acute Otitis Media6,154 of 9,020

6,287 of 7,778

-12.6 points

-13.9 to -11.3

16,798NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Duration for Pediatric Acute Otitis Media7,565 of 9,020

7,281 of 7,778

-9.7 points

-10.7 to -8.8

16,798NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

Bococizumab (PF-04950615) vs Placebo: deaths from any cause72 of 8,386

65 of 8,374

0.1 points

-0.2 to 0.4

16,760NCT01975376

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Bococizumab (PF-04950615) vs Placebo: serious adverse events1,060 of 8,386

986 of 8,374

0.9 points

-0.1 to 1.9

16,760NCT01975376

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Home Assessment and Initiation of ART vs Clinic-based ART Assessment and Initiation: Reporting of HIV-positive Results490 of 8,194

278 of 8,466

2.7 points

2.1 to 3.3

16,660NCT01414413

Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi

Home Assessment and Initiation of ART vs Clinic-based ART Assessment and Initiation: Uptake of Home-based HIV Testing5,287 of 8,194

4,433 of 8,466

12.2 points

10.7 to 13.6

16,660NCT01414413

Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi

Home Assessment and Initiation of ART vs Clinic-based ART Assessment and Initiation: ART Initiation181 of 8,194

63 of 8,466

1.5 points

1.1 to 1.8

16,660NCT01414413

Home Assessment and Initiation of Antiretroviral Therapy for HIV in Malawi

Saxagliptin vs Placebo: Participants With Event of Death420 of 8,280

378 of 8,212

0.5 points

-0.2 to 1.1

16,492NCT01107886

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Saxagliptin vs Placebo: Participants With Any Event From the Composite of Cardiovascular Death (CV Death), Non-fatal Myocardial Infarction (MI), or Non-fatal Ischaemic Stroke613 of 8,280

609 of 8,212

-0.0 points

-0.8 to 0.8

16,492NCT01107886

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Saxagliptin vs Placebo: Participants With Any Event From the Composite of CV Death, Non-fatal MI, Non-fatal Ischaemic Stroke, Hospitalisation for Heart Failure, Hospitalisation for Unstable Angina Pectoris, or Hospitalisation for Coronary Revascularisation1,059 of 8,280

1,034 of 8,212

0.2 points

-0.8 to 1.2

16,492NCT01107886

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Saxagliptin vs Placebo: serious adverse events2,114 of 8,280

2,075 of 8,212

0.3 points

-1.1 to 1.6

16,492NCT01107886

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Women Who Enrolled in EAQ201 vs Women Who Enrolled in TMIST: Compare the Proportion of WOC in TMIST Participants vs EAQ201 Participants1 of 14

1,138 of 16,427

0.2 points

-5.7 to 24.5

16,441NCT05076266

COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

ARCT-154 vs Placebo: Number of Participants With a First Occurrence of COVID-19 Irrespective of Prior Infection223 of 8,492

457 of 7,941

-3.1 points

-3.8 to -2.5

16,433NCT05012943

The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

ARCT-154 vs Placebo: Number of Participants With Death Due to COVID-191 of 8,492

9 of 7,940

-0.1 points

-0.2 to -0.0

16,432NCT05012943

The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

ARCT-154 vs Placebo: Number of Participants With a First Occurrence of Severe COVID-192 of 8,492

43 of 7,940

-0.5 points

-0.7 to -0.4

16,432NCT05012943

The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)

Vaccine vs Placebo: deaths from any cause85 of 8,197

75 of 8,198

0.1 points

-0.2 to 0.4

16,395NCT00223080

HIV Vaccine Trial in Thai Adults

Vaccine vs Placebo: serious adverse events1,175 of 8,197

1,219 of 8,198

-0.5 points

-1.6 to 0.5

16,395NCT00223080

HIV Vaccine Trial in Thai Adults

Clostridium Difficile Vaccine vs Placebo: Number of Participants With Recurrent Episodes of CDI (Definition 2) After Dose 26 of 8,139

3 of 8,184

0.0 points

-0.0 to 0.1

16,323NCT03090191

Clostridium Difficile Vaccine Efficacy Trial

Clostridium Difficile Vaccine vs Placebo: Number of Participants With Recurrent Episode of CDI (Definition 2) After Dose 2 and Before Dose 31 of 8,139

0 of 8,184

0.0 points

-0.0 to 0.1

16,323NCT03090191

Clostridium Difficile Vaccine Efficacy Trial

No PN Use (Project B) vs PN Use (Project B): Necrotising Enterocolitis (Project B)285 of 8,146

660 of 8,146

-4.6 points

-5.3 to -3.9

16,292NCT03767634

Outcomes Following Early Parenteral Nutrition Use in Preterm Neonates

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=27

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT06027593-bb375b40",
        "title": "Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Use for Children With Acute Otitis Media",
        "summary": "6154 of 9020 against 6287 of 7778; risk difference -12.6 points, 95% interval -13.9 to -11.3; NCT06027593, Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions",
        "record": "/library/comparisons/NCT06027593-bb375b40",
        "nct_id": "NCT06027593",
        "kind": "outcome",
        "participants": 16798,
        "risk_difference": {
          "value": -0.12604383618814563,
          "lower": -0.13899217185517027,
          "upper": -0.1130053205072896
        },
        "group_1": "6,154 of 9,020",
        "group_2": "6,287 of 7,778",
        "difference": "-12.6 points",
        "interval": "-13.9 to -11.3",
        "trial_title": "Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions"
      },
      {
        "id": "NCT06027593-cf5d5b37",
        "title": "Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Antibiotic Duration for Pediatric Acute Otitis Media",
        "summary": "7565 of 9020 against 7281 of 7778; risk difference -9.7 points, 95% interval -10.7 to -8.8; NCT06027593, Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions",
        "record": "/library/comparisons/NCT06027593-cf5d5b37",
        "nct_id": "NCT06027593",
        "kind": "outcome",
        "participants": 16798,
        "risk_difference": {
          "value": -0.09741002965325474,
          "lower": -0.10674283098324994,
          "upper": -0.08806088279567512
        },
        "group_1": "7,565 of 9,020",
        "group_2": "7,281 of 7,778",
        "difference": "-9.7 points",
        "interval": "-10.7 to -8.8",
        "trial_title": "Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=28",
  "request_id": "misPjIbvvf1EhOpz"
}
trial-comparisons-2026-03-23-0.1.0Next page

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Open193,990 genes2026-11-11

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Open611,552 trials2026-11-12

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

For invited accounts.

Opens sequences.conductscience.org

By invitation39,249,078 sequences2026-11-05

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?